Johnson & Johnson (JNJ)

NYSE: JNJ · USD

$258

+2.65 (+1.0%)· Recorded snapshot

Coverage state: Latest published research available

Market snapshot recorded 2026-08-06 02:00 UTC. Latest published research analyzed 2026-05-08 · historical · sources unverified. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate a fresh JNJ analysis

The published report stays available while a new owner-requested analysis runs.

StockMarketAgent Research · Analyzed 2026-05-08

Our latest published analysis: JNJ rated Strong Buy

JNJ is rated Strong Buy at $222.51 versus the reconciled fair value midpoint of $331.57, implying +49.01% upside/downside. Confidence is separately disclosed at 88/100.

Fair value (mid)

$332 / share

$245 – $419

Upside to FV

+49.0%

from $258

Confidence

88/100

Moat

9/10

Read full analysis

Market cap	$535.6B
Revenue (ttm)	97.9B
Net income (ttm)	21B
EPS (ttm)	$8.63
Shares out	2.4B
P/E (trailing)	29.6x
P/E (forward)	17.5x
Dividend	$5.36 (2.08%)
Volume	6,467,819
Beta	0.23
Price target	$271	+5.2%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 97.9B
Net income (ttm): 21B
EPS (ttm): $8.63
P/E (trailing): 29.6x
P/E (forward): 17.5x
Market cap: $535.6B

Item	P1	P2	P3	P4	Trend
Period	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$79.99B	$85.16B	$88.82B	$94.19B	+5.6%
Gross profit	$55.39B	$58.61B	$61.35B	$63.94B	+4.9%
Operating income	$21.01B	$22.01B	$21.25B	$25.60B	+6.8%
Net income	$17.94B	$35.15B	$14.07B	$26.80B	+14.3%
EPS (diluted)	$6.73	$13.72	$5.79	$11.03	+17.9%
EBITDA	$26.61B	$23.32B	$24.78B	$41.06B	+15.6%
R&D	$14.14B	$15.09B	$17.23B	$14.67B	+1.2%
SG&A	$20.25B	$21.51B	$22.87B	$23.68B	+5.4%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	4.6T	35.8x	9.8x	101.6%	+6.1%	+54.6%	Sell
ABNB	Airbnb Inc.	90B	37.2x	6.8x	16.8%	+24.4%	+16.7%	Hold
ADBE	Adobe Inc.	103.4B	14.9x	4.1x	60.7%	+11.9%	-23.2%	Strong Buy
ABBV	AbbVie Inc.	430.9B	69.6x	6.7x	17.7%	+3.7%	+26.6%	Hold
ABT	Abbott Laboratories	186.8B	34.9x	4.0x	7.5%	+3.0%	-15.5%	Strong Buy
AMGN	Amgen Inc.	218.9B	25.2x	5.7x	19.8%	+8.4%	+39.0%	Strong Buy

All JNJ indicators

Market & fundamental data

Available fields

293

Groups with data

Currency

USD

Showing 293 of 293 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000200406
Company name	Johnson & Johnson
Country	United States
Country code	US
Cusip	478160104
Employees	138,200
Employees Change	100%
Employees Change Percent	0.07
Enterprise value	$649.1B
Exchange	NYSE
Financial currency	USD
First seen	2026-05-09
In Index	SP500, DOW30
Industry	Drug Manufacturers - General
Industry PE	31.36
Industry PE Fwd	17.85
IPO Date	1944-09-24
Isin	US4781601046
Last refreshed	2026-08-06
Market cap	$620.8B
Market cap category	Mega-Cap
Price	$258
Price currency	USD
Rev Per Employee	708,603.47x
Sector	Healthcare
Sector PE	48.99
Sector PE Fwd	22.9
Sic	2834
Symbol	JNJ
Tags	pharmaceuticals
Website	https://www.jnj.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	3.39%
EV Earnings	30.85x
EV Sales Forward	6.22x
EV/EBIT	24.83x
EV/EBITDA	19.15x
EV/FCF	29.18x
EV/Sales	6.63x
FCF yield	3.58%
Forward P/E	22.73x
P/B ratio	7.23x
P/E ratio	29.55x
P/S ratio	6.34x
PE Ratio10 Y	46x
PE Ratio3 Y	18.31x
PE Ratio5 Y	21.36x
PEG ratio	2.79x
PS Forward	5.95x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	26.69%
EBITDA Margin	34.61%
FCF margin	22.71%
Gross margin	68.14%
Gross Profit	$66.7B
Gross Profit Growth	7.63%
Gross Profit Growth Q	7.22%
Gross Profit Growth3 Y	5.43%
Gross Profit Growth5 Y	2.23%
Net Income	$21B
Net Income Growth	-7.17%
Net Income Growth Q	-0.05%
Net Income Growth Years	1%
Net Income Growth3 Y	17.24%
Net Income Growth5 Y	3.44%
Pretax Margin	25.73%
Profit Margin	21.48%
Profit Per Employee	$152,221
Profitable Quarters	$13
Profitable Years	35
ROA	8.59
Roa5y	8.04
ROCE	17.88
ROE	25.74
Roe5y	24.21
ROIC	19.92
Roic5y	23.67

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	10.58%
Cagr15y	13.17%
Cagr1y	54.41%
Cagr20y	10.4%
Cagr3y	18.48%
Cagr5y	11.33%
Div CAGR10	5.47%
Div CAGR3	4.4%
Div CAGR5	4.98%
EPS Growth	-7.58
EPS Growth Q	-0.87
EPS Growth Years	1
EPS Growth3 Y	20.48
EPS Growth5 Y	5.34
FCF Growth	19.92%
FCF Growth Q	157.32%
FCF Growth3 Y	15.21%
FCF Growth5 Y	-0.29%
OCF Growth	19.89%
OCF Growth Q	122.18%
OCF Growth10 Y	4.38%
OCF Growth3 Y	13.12%
OCF Growth5 Y	1.12%
Revenue Growth	8.06x
Revenue Growth Q	6.6x
Revenue Growth Quarters	12x
Revenue Growth Years	4x
Revenue Growth3 Y	5.95x
Revenue Growth5 Y	1.89x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.5
Assets	$201.1B
Cash	$20.8B
Current Assets	$59.8B
Current Liabilities	$54.9B
Debt	$49B
Debt EBITDA	$1.45
Debt Equity	$0.58
Debt FCF	$2.2
Equity	$85B
Interest Coverage	25.83
Liabilities	$116.1B
Long Term Assets	$141.3B
Long Term Liabilities	$61.2B
Net Cash	$-28.3B
Net Cash By Market Cap	$-4.56
Net Debt EBITDA	$0.83
Net Debt Equity	$0.33
Net Debt FCF	$1.27
Tangible Book Value	$-11.7B
Tangible Book Value Per Share	$-4.87
WACC	5.25

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.09
Inventory Turnover	2.19
Net Working Capital	$-4.2B
Quick ratio	0.73
Working Capital	$4.9B
Working Capital Turnover	$37.69

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.53%
Dividend Growth	3.94%
Dividend Growth Years	64%
Dividend per share	$5.36
Dividend Years	64
Dividend Yield	2.08%
Ex Div Date	2026-08-25
Last Dividend	$1.34
Payout Frequency	Quarterly
Payout Ratio	62.13%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	173.43%
1Y total return	54.37%
200-day SMA	227.4
3Y total return	66.33%
50-day SMA	246.6
50-day SMA vs 200-day SMA	50over200
5Y total return	71.03%
All Time High	274.9
All Time High Change	-6.3%
All Time High Date	2026-07-28
All Time Low	0.52
All Time Low Change	49,522.42%
All Time Low Date	1968-03-14
ATR	6.23
Beta	0.23
Beta1y	-0.48
Beta2y	-0.02
Ch YTD	24.47
High	259.3
High52	274.9
High52 Date	2026-07-28
High52ch	-6.3%
Low	254.5
Low52	169.7
Low52 Date	2025-08-05
Low52ch	51.84%
Ma50ch	4.44%
Premarket Change Percent	0.13
Premarket Price	$255
Premarket Volume	22,522
Price vs 200-day SMA	13.28%
RSI	53.64
RSI Monthly	73.88
RSI Weekly	64.52
Sharpe ratio	2.26x
Sortino ratio	4.04
Total Return	1.55%
Tr YTD	25.85
Tr15y	539.63%
Tr1m	-2.07%
Tr1w	-2.99%
Tr3m	15.55%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	23
Analyst Count Top	12
Analyst Price Target Top	$283
Analyst Ratings	Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$2.85
Earnings EPS Estimate Growth	2.89
Earnings Revenue Estimate	25,048,572,504x
Earnings Revenue Estimate Growth	5.5x
Operating Income	$27.1B
Operating Income Growth	16.63
Operating Income Growth Q	7.67
Operating Income Growth3 Y	5.24
Operating Income Growth5 Y	2.94
Operating margin	27.69
Price target	$271
Price Target Change	$5.23
Price Target Change Top	$9.83

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	2,405,909,781%
Float Percent	99.83%
Net Borrowing	-1,572,000,000
Shares Insiders	0.04%
Shares Institutions	76.08%
Shares Out	2,409,898,597
Shares Qo Q	-0.21%
Shares Yo Y	0.53%
Short Float	1.14%
Short Ratio	3.04
Short Shares	1.14

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$20.8B
Adjusted OCF	26,194,000,000
Average Volume	7,769,530.9x
Bv Per Share	35.28
CAPEX	$-5.4B
Ch10y	108
Ch15y	316.5
Ch1m	-2.07
Ch1w	-2.99
Ch1y	50.6
Ch20y	305.5
Ch3m	14.89
Ch3y	52.38
Ch5y	48.59
Ch6m	9.86
Change	1.04%
Change From Open	0.92
Close	254.9
Days Gap	0.13
Depreciation Amortization	7,751,000,000
Dollar Volume	1,666,045,496.2
Earnings Date	2026-07-15
Earnings Time	bmo
EBIT	$26.1B
EBITDA	$33.9B
EPS	$8.63
F Score	7
FCF	$22.2B
FCF EV Yield	3.43x
FCF Per Share	$9.23
Financing CF	-18,543,000,000
Fiscal Year End	December
Founded	1,886
Goodwill	48,479,000,000
Graham Number	82.75694
Graham Upside	-67.87
Income Tax	$4.2B
Investing CF	-7,177,000,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-07-15
Last Report Date	2026-06-28
Last Split Date	2001-06-13
Last Split Type	Forward
Last10k Filing Date	2026-02-11
Lynch Fair Value	$43.13
Lynch Upside	-83.26
Ma150	236.7
Ma150ch	8.8%
Ma20	256.6
Ma20ch	0.37%
Net CF	1,845,000,000
Next Earnings Date	2026-10-13
Open	255.3
Optionable	Yes
P FCF Ratio	27.91
P FCF Ratio SBC	29.8
P OCF Ratio	22.49
P OCF Ratio SBC	23.7
Payment Date	2026-09-08
Position In Range	64.33
Post Close	257.6
Postmarket Change Percent	0.18
Postmarket Price	$258
Ppne	23,582,000,000
Pre Close	254.9
Price Date	2026-08-05
Price EBITDA	$18.32
Relative Volume	0.83x
Revenue	97,929,000,000x
SBC By Revenue	1.44x
Share Based Comp	1,414,000,000
Tax By Revenue	4.25x
Tax Rate	16.51%
Tr20y	623.64%
Tr6m	11.08%
Us State	New Jersey
Views	589
Volume	6,467,819
Z Score	4.74

Frequently asked questions

About this JNJ report

What is the latest published JNJ stock rating?

Johnson & Johnson is shown with strong buy in the latest published report, analyzed 2026-05-08. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full JNJ analysis?

The full latest published report, analyzed 2026-05-08, lives at /stocks/JNJ/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair-value range is used for JNJ?

The latest published report analyzed 2026-05-08 frames JNJ around USD 245 to USD 419. This is a dated valuation range, not a live market price; check the valuation, sensitivity, and bear-case tabs before making a decision.

How often is the JNJ page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-05-08). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

Johnson & Johnson (JNJ)

Coverage state: Latest published research available

Generate a fresh JNJ analysis

Our latest published analysis: JNJ rated Strong Buy

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · JNJ

Valuation

Profitability

Balance sheet

Trading

Position sizing & entry playbook

Next earnings

Sector percentile context

All JNJ indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on JNJ

Frequently asked questions